Columbus, OH

Houston, TX

Researchers from the University of Houston identified CD8-fit T cells with high motility and serial killing abilities, potentially enhancing T-cell cancer therapies. The study used the TIMING approach and RNA sequencing, revealing molecular signatures that predict positive patient outcomes. A group of cancer researchers from the University of Houston has...

Cancer Breakthrough: Scientists Discover Game-Changing New Type of T Cells

BGR.com

GSK announced a major breakthrough concerning cancer therapy. A drug called Jemperli (dostarlimab) showed impressive results in a phase 2 trial at the Memorial Sloan Kettering Cancer Center (MSK). The study included 42 patients suffering from mismatch repair deficient (dMMR) locally advanced rectal cancer, a type of bowel cancer.
Used as a first-line treatment and an alternative to chemotherapy and surgery, Jemperli cured cancer in all patients, showing “an unprecedented 100% clinical complete response rate.” Tests that followed showed no evidence of remaining tumors. Moreover, the first 24 of the 42 patients were observed after an average time of 26.3 months,...

New bowel tumor drug helped cure cancer in 100% of cases

Medical News Today

A new cell study has shown the common type 2 diabetes medication metformin alters levels of microRNAs that target genes to slow down the growth and multiplication of colorectal cancer cells. The researchers say their findings could lead to new RNA therapeutics for cancer prevention and treatment.

Metformin slows colorectal cancer growth using microRNAs, study finds

The signs that thyroid cancer has spread can vary depending on where in the body it has traveled to. Thyroid cancers often spread to the nearby lymph nodes and the lungs, bone, brain, and liver. For all types of thyroid cancer, early detection and personalized treatment plans are crucial for...

What are some signs that thyroid cancer has spread?

Physician scientists from City of Hope, one of the largest cancer research and treatment organizations in the United States, found that people with metastatic kidney cancer who orally took a live biotherapeutic product called CBM588 while in treatment with immunotherapy and enzymatic tyrosine kinase inhibitors experienced improved health outcomes. The phase 1 trial was published today in Nature Medicine.

Changing the gut microbiome improves health outcomes for people new metastatic kidney cancer

Community Voices represent independent, third-party users who have joined our contributor program but not yet verified their accounts. Community Voices are expected, like all users, to adhere to our Community Standards.

community_voice

Fareeha Arshad

In a recent study from China, researchers have revealed a potential dual benefit of a new antidepressant in combating both depression and certain types of cancer. Ansofaxine hydrochloride, an oral antidepressant, has shown promise in inhibiting the growth of colon cancer cells in both cell cultures and mice. When combined strategically with anti-tumour drugs, ansofaxine hydrochloride bolsters the immune system and triggers programmed cell death in cancer cells.

New Antidepressant Shows Dual Promise in Fighting Depression and Colon Cancer

Health

Medically reviewed by Gagandeep Brar, MDMedically reviewed by Gagandeep Brar, MDLung cancer is a type of cancer that grows in your lung tissue. Stages of cancer span from 0-4, with stage 4 being the most advanced stage of lung cancer. Lung cancer is often diagnosed in the later stages because symptoms may be difficult to detect before stage 3 or 4. There are two main types of lung cancer—small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).Small cell lung cancer (SCLC) makes up about 10-15% of all lung cancer cases, and non-small cell lung cancer (NSCLC) makes up...

Stage 4 Lung Cancer

Ohtuvayre is the first inhaled product with a novel mechanism of action for chronic obstructive pulmonary disease to be approved in 20 years. The FDA has approved Verona Pharma’s Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Classified as a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), the treatment combines bronchodilator and non-steroidal anti-inflammatory effects in one molecule. According to the company, this marks the first time in 20 years that an inhaled product with a novel mechanism of action has been approved for COPD maintenance.1.

FDA Approves Verona’s Ohtuvayre for the Maintenance Treatment of Chronic Obstructive Pulmonary Disease

When Angela received her first shot at the Lombardi Comprehensive Cancer Center in early 2020, Covid-19 was months away. Far from a household name, mRNA vaccines were mostly relegated to lab studies. Yet the jab she received was made of the same technology. A melanoma patient, Angela had multiple malignant...

mRNA Cancer Vaccines Spark Renewed Hope as Clinical Trials Gain Momentum

Approval of Epkinly was based on results from the Phase I/II EPCORE trial in patients with relapsed or refractory follicular lymphoma who have already completed two or more lines of systemic therapy. The FDA has approved Genmab A/S and AbbVie's Epkinly (epcoritamab-bysp) for the treatment of adults with relapsed or...

FDA Approves Genmab’s Epkinly to Treat Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy

Review the multiple uses of metformin. A recent article on the multiple uses of metformin brings up the important topic of repurposing medications.1 Repurposing has been around since the advent of modern medicine. One prominent example is the use of chlorpromazine (CPZ) as an antipsychotic.2 Chlorpromazine was first synthesized in 1951 as a potentiator of general anesthesia.2 The psychiatric benefits were found later by Henri Laborit, a surgeon in the French army. He was doing research with artificial hibernation in prevention of surgical shock.2 Laborit employed the drug as an adjunct to anesthetics.2 He observed that CPZ at doses of 50 mg to 100 mg produced a lowering of body temperature, sedation, and disinterest without loss of consciousness.2 He was able to persuade his colleagues in the military hospital in Paris to try CPZ in the treatment of one of their patients who was experiencing psychotic agitation.2 Laborit hypothesized that since cooling with water had been used to treat agitation in France, the drug would have a similar effect.2 The mechanism of action was not fully known, and it was thought that it worked in controlling agitation because of its cooling effect and induction of “artificial hibernation” in patients.2 The pharmacological mechanism was not fully understood until many years later and the way it has impacted the practice of psychiatry needs no introduction. These “happy accidents” in medicine have played a vital role in getting where we are right now compared with just 50 years ago. This begs the question, are we onto another “happy accident” with metformin? There is an accumulating body of evidence that metformin may have benefits in aging that are beyond its effect on glycemic control.3.

Metformin, Inflammation, the Gut Microbiome, and Health Span: Connecting the Dots

More than half of the patients who received mitazalimab plus chemotherapy experienced an unconfirmed objective response in the phase 2 OPTIMIZE-1 study. Mitazalimab in combination with modified leucovorin calcium/folinic acid, fluorouracil, irinotecan, and oxaliplatin (mFOLFIRINOX) produced an overall survival (OS) benefit and elicited responses among patients with metastatic pancreatic cancer, according to a press release on 18-month follow-up data from the phase 2 OPTIMIZE-1 trial (NCT04888312).1.

Mitazalimab/Chemo Prolongs Survival, Responses in Pancreatic Cancer

Cancer Health

Clinical trials play a vital role in many aspects of our fight against cancer. Not only do they help test cutting-edge treatments that could be more effective and better tolerated, but they also help experts develop new methods of prevention, screening, diagnosis and care. Trials can even lead to improved communication models, medical devices and much more.

2024 Cancer Health 25: People Who Power Clinical Trials

rolling out

Pancreatic cancer is a daunting diagnosis that affects thousands of people worldwide every year. One of the most challenging aspects of this disease is its subtlety; the symptoms often mimic those of other, less severe conditions. This similarity can lead to delayed diagnosis and treatment, significantly impacting the prognosis. Understanding why pancreatic cancer symptoms resemble other diseases’ symptoms is crucial for early detection and better outcomes. This article will delve into the reasons behind this symptom overlap, explore common symptoms of pancreatic cancer, and provide insights on differentiating these symptoms from other ailments.

Why pancreatic cancer symptoms are similar to other diseases

Isolation by size of epithelial tumor cells (ISET), Peritoneal metastasis, Gastric cancer, Free cancer cells, Prognosis, Occult peritoneal metastasis. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.

Positive peritoneal lavage fluid cytology based on isolation by size of epithelial tumor cells indicates a high risk of peritoneal metastasis

Positron emission tomography (PET) is a type of imaging scan that doctors might use when diagnosing and treating non-Hodgkin’s lymphoma (NHL). It can be useful for identifying and staging the cancer. Non-Hodgkin’s lymphoma (NHL) is a cancer of the lymph nodes. These are small structures in the neck, armpits,...

What is the role of PET scans in non-Hodgkin’s lymphoma?

Medically reviewed by Archana Sharma, DOMedically reviewed by Archana Sharma, DOResearchers identified two main types of lung cancer: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), which is the most common type. Adenocarcinoma (also known as adenocarcinoma lung cancer or lung adenocarcinoma) is the most common type of NSCLC. While NSCLC accounts for 85% of all lung cancer cases, 40% of diagnoses are due to adenocarcinoma, which can cause symptoms like chronic cough and shortness of breath, among others. Adenocarcinoma is a term for cancers that develop from cells in your glands, which are organs that release substances...

Adenocarcinoma Lung Cancer

Accelerated approval for Krazati is based on results from the Phase 1/2 KRYSTAL-1 study, which demonstrated a 34% objective response rate in patients with previously treated, locally advanced, or metastatic colorectal cancer. The FDA has granted accelerated approval to Bristol Myers Squibb’s (BMS) Krazati (adagrasib) in combination with cetuximab to...

FDA Grants Accelerated Approval to Bristol Myers Squibb’s Krazati for Previously Treated, Locally Advanced, or Metastatic Colorectal Cancer

Among individuals with primary biliary cholangitis (PBC), pruritus and fatigue are the most common symptoms of the disorder, with research warranted to elucidate the pathophysiology of the disease, as well as to assess effective treatments for improving patient survival and quality of life (QoL). The current review, published recently in...

Pruritus, Fatigue Most Common Symptoms in PBC, Need Treatment Options

Black Coffee and Blue Jeans

Thyroid cancer is a type of cancer that originates in the thyroid gland, a butterfly-shaped gland located at the base of the neck, just below the Adam's apple. The thyroid gland produces hormones that regulate heart rate, blood pressure, body temperature, and your weight. There are several types of thyroid cancer, to include: Papillary Thyroid Cancer, (the most common type), Follicular Thyroid Cancer, hurthle cell cancer, Medullary Thyroid Cancer, , and Anaplastic Thyroid Cancer, the rarest type but most aggressive, and thyroid lymphoma.

Thyroid Cancer: Risks, Symptoms & Treatments

NewsBreak

Immunotherapy for Cold Tumors: REGN7075 Effective in Early Trials

Neil Segal, MD, discussed findings from a phase 1/2 trial investigating REGN7075 in patients with solid tumors refractory to immunotherapy. June is Cancer Immunotherapy Month, and...

Immunotherapy for Cold Tumors: REGN7075 Effective in Early Trials

Comments / 0